[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":107},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100602813","extra-luteinizing-hormone-improve-embryo-quality-in-ivf-patients-with-low-lh-during-long-gnrh-agonist-treatment-100602813",false,"NCT07128394","Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","Exogenous Luteinizing Hormone Supplementation to Improve Embryo Quality in Patients With Excessive LH Suppression During a Long GnRH-Agonist Protocol: A Randomized Controlled Trial","ELH-IVF","Inclusion Criteria:\n\n* Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing in vitro fertilization\u002Fintracytoplasmic sperm injection (IVF\u002FICSI) treatment using the long-acting GnRH agonist protocol.\n\nSerum luteinizing hormone (LH) level \\\u003C0.5 U\u002FL after pituitary downregulation. Normal uterine cavity as confirmed by hysteroscopy, sonohysterography, or hysterosalpingography within 6 months.\n\nWritten informed consent provided prior to participation.\n\nExclusion Criteria:\n\n* Polycystic ovary syndrome (PCOS). History of recurrent implantation failure (RIF). Presence of endometriosis or adenomyosis. History of ovarian surgery. Ovarian cysts ≥3 cm or with suspected malignancy. Poor ovarian reserve (antral follicle count \\\u003C5, anti-Müllerian hormone \\\u003C1.1 ng\u002FmL, or baseline FSH \\>10 IU\u002FL).\n\nChromosomal abnormalities in either partner. Systemic diseases such as uncontrolled hypertension, diabetes, thyroid disorders, or autoimmune diseases.\n\nContraindications to ovarian stimulation medications or pregnancy.","FEMALE","20 Years","37 Years",{"count":21,"type":22},590,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.",[28,29],"Infertility, Female","Luteinizing Hormone (LH)",[31,32,33,34,35,36],"Luteinizing Hormone","Long GnRH Agonist Protocol","Excessive LH Suppression","Controlled Ovarian Stimulation","In Vitro Fertilization","Embryo Quality","RECRUITING","2025-08-13",{"date":40,"type":41},"2025-08-19","ACTUAL",{"date":43,"type":41},"2024-02-01",{"date":45,"type":22},"2026-11-30",{"name":47,"class":48},"Nanjing University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":49},"100559982","phase-4-potential-benefit-of-r-hlh-addition-in-patients-aged-35-to-40-under-ovarian-stimulation-treatment-100559982","NCT06571214","Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment","An Exploratory, Randomized, Open-label, Controlled Study to Evaluate the Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment","Inclusion Criteria:\n\n* Age 35 to 40 (including 40)\n* 18.5\\\u003CBMI\\\u003C28 kg\u002Fm2\n* AFC up to 14\n* First or second ART cycle\n* Planned for ovarian stimulation with GnRH-antagonist for down-regulation\n* Ejaculated sperm\n\nExclusion Criteria:\n\n* Contraindications to ART treatment\n* History of two or more spontaneous miscarriages\n* History of two or more implantation failures after fresh or frozen-warmed embryo transfers\n* Diagnosis of severe endometriosis\n* Patients with endocrine and metabolic diseases (diabetes mellitus, hypogonadotropic amenorrhea, genital system tumors, hyperprolactinemia, etc.)\n* Confirmed chromosomal abnormalities","35 Years","40 Years",{"count":60,"type":22},300,[62],"PHASE4","This will be an exploratory, prospective, randomized, open-label and controlled trial to evaluate the potential benefit of r-hFSH:r-hLH 2:1 co-treatment starting from COS D1 versus r-hFSH alone in patients aged 35 to 40 under ovarian stimulation treatment.\n\nAfter signing informed consent form (ICF), all eligible participants will be randomly assigned in a 1:1 ratio to either treatment or control group, and GnRH antagonist protocol will be used in both treatment and control groups.",[65],"Infertility",[67,68,69,70],"recombinant human LH","recombinant human FSH","ovarian stimulation treatment","advanced maternal age population","NOT_YET_RECRUITING","2024-08-25",{"date":74,"type":41},"2024-08-27",{"date":76,"type":22},"2024-09-01",{"date":78,"type":22},"2027-01-30",{"name":47,"class":48},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":49},"100529501","early-phase-1-umbilical-cord-artery-derived-perivascular-stem-cells-for-the-critical-limb-ischemia-therapy-100529501","NCT06174597","Umbilical Cord Artery-derived Perivascular Stem Cells for the Critical Limb Ischemia Therapy","Efficacy and Safety of Umbilical Cord Artery-derived Perivascular Stem Cells in Patients With Critical Limb Ischemia","Inclusion Criteria:\n\n1. Aged between 18 and 80, of any gender;\n2. Diagnosed with lower extremities ischemia, classified as Rutherford Stage IV-V, affecting at least one limb. If both lower limbs have ischemic disease, the researcher will determine which affected limb will be studied. The resting ankle systolic pressure (dorsalis pedis artery or posterior tibial artery) of the affected limb is less than 60mmHg, or the toe systolic pressure is less than 40 mmHg, or the Ankle-Brachial Index (ABI) is less than 0.50;\n3. Within the last month, Digital Subtraction Angiography (DSA), Computed Tomography Arteriography (CTA), Magnetic Resonance Angiography (MRA)，or vascular ultrasound has confirmed that one or more of the arteries (superficial femoral artery, i.e., the femoral artery below the deep femoral artery branch, the popliteal artery, and its following arteries) have a stenosis of ≥75% or occlusion;\n4. Patient experiences rest pain in the limb due to ischemia for at least two weeks;\n5. Inoperable or not suitable for endovascular treatment，or no obvious improvement after surgical treatment;\n6. Expected lifespan \\>2 years;\n7. Good compliance, accepting dietary control and medication treatment, with an informed consent form signed by the patient themselves or their legal representatives.\n\nExclusion Criteria:\n\n1. Acute ischemic disease of the lower limb(s) occurred within the past 2 weeks, or patients with acute progression of lower extremity arterial ischemic disease, or those with local\u002Fdiffuse gangrene;\n2. Unsatisfactory evaluation of condition stability after vascular reconstruction surgery or sympathetic nerve removal surgery performed within 4 weeks，or possibility of undergoing amputation in the next 4 weeks;\n3. Stenosis of ≥75% in the main-iliac artery;\n4. Diabetic patients with HbA1c \\> 10%;\n5. Abnormal laboratory test results that meet any of the following criteria:i. Abnormal blood routine examination: Hemoglobin (HGB)\\\u003C80 g\u002FL, or white blood cell count (WBC)\\\u003C3.0×10\\^9\u002FL, or platelet count (PLT)\\\u003C50×10\\^9\u002FL; ii. Abnormal liver function: Aspartate aminotransferase (AST)\\>2 times the upper limit of normal (ULN), or alanine aminotransferase (ALT)\\>2×ULN, total bilirubin (TBIL)\\>2×ULN; iii. Severe renal dysfunction requiring dialysis treatment;iv. Other abnormal laboratory testing indicators that researchers believe may affect the evaluation of trial results;\n6. Diseases unsuitable for clinical trials, or contraindications to surgery: i. Difficult-to-control hypertension (\\>180\u002F110mmHg), severe heart failure (NYHA IV), or EF\\\u003C30%;ii. Patients who have had a stroke, brain hemorrhage, myocardial infarction, or unstable angina in the past one month; iii. Patients with malignant tumors;iv. Receiving immunosuppressants, hemodialysis, chemotherapy, and radiotherapy; v. Active infection, HIV antibody positive, Hepatitis C antibody positive, Hepatitis B (HBsAg positive and Hepatitis B virus DNA quantitative detection value greater than 1×10\\^3 IU\u002FmL); vi. Serious infections (like cellulitis, osteomyelitis etc.) in the observational limb, exposure of distal fascia or skeleton, unable to maintain wound care for ulcers in the surgical area etc.; vii. History of major surgery or serious injury within the last one months;\n7. During the trial, taking the following drugs at doses greater than stated below, except those who stop medication or adjust the dose to the prescribed dose for 7 days according to the washout period: i. COX-2 inhibitor drugs (such as nimesulide); ii. Aspirin (more than 100 mg\u002Fday);iii. High-dose steroid medications, excluding inhaled steroids; iv. Opioid analgesics (like morphine) for 2 weeks or longer;\n8. Congenital or acquired immunodeficiency;\n9. Pregnant women or those planning pregnancy;\n10. Diseases like pulmonary heart disease and mental illness that researchers believe are unstable and cannot complete the trial, or comorbidities that could interfere with safety checks and effectiveness assessments;\n11. Currently participating in other clinical trials.","ALL","18 Years","80 Years",{"count":91,"type":22},40,[93],"EARLY_PHASE1","This clinical trial included 2 periods. During the first period, it was a single arm study to explore the safety of umbilical cord artery-derived stem cells (UCA-PSCs) in the treatment of patients with critical limb ischemia (CLI). During the second perid, it was a single-center, randomized, controlled prospective study to determine the efficacy of the UCA-PSCs treatment. Those who had CLI were enrolled in the study.",[96],"Critical Limb Ischemia",[96,98],"Umbilical cord artery-derived perivascular stem cells","2023-12-07",{"date":101,"type":41},"2023-12-18",{"date":103,"type":41},"2023-06-30",{"date":105,"type":22},"2026-06-30",{"name":47,"class":48},""]